RT Journal Article SR Electronic T1 Protocol for 18F-PSMA PET imaging in staging and management of prostate cancer – a retrospective cohort study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.10.26.21265520 DO 10.1101/2021.10.26.21265520 A1 Byrne, Matthew H V A1 Ranasinha, Nithesh A1 Bryant, Richard J A1 Hamdy, Freddie C A1 Leslie, Tom A1 Miah, Saiful A1 Gleeson, Fergus A1 MacPherson, Ruth A1 Tuthill, Mark A1 Protheroe, Andy A1 Camilleri, Philip A1 Turner, Phil A1 Sabharwal, Ami A1 Andrade, Gerard A1 Lamb, Alastair D YR 2021 UL http://medrxiv.org/content/early/2021/10/27/2021.10.26.21265520.abstract AB Background MRI, bone scan, and CT staging is recommended in the staging of prostate cancer. However, prostate-specific membrane antigen positron emission tomography (PSMA PET) could be superior in detection of local and distant prostate cancer cells. Most PSMA PET scans for prostate cancer are performed with a Gallium-68 ligand, with the Fluorine-18 (18F) ligand being introduced more recently. Methods: We will conduct a retrospective review of electronic patient records for all consecutive patients who underwent preoperative 18F-PSMA PET scan for prostate cancer from its introduction at our centre in 2019. We will compare PET scans with other imaging modalities and evaluate its use in diagnosis and management decisions for prostate cancer.Conclusions Understanding the role of 18F-PSMA PET in diagnosis and management could influence the diagnostic pathway of primary and secondary prostate cancer.Trial registration Not applicable.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved as a service evaluation by the Audit Department at Oxford University Hospitals Trust, UK and ethical approval was not required for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable.